

ImmunoCAP™ Specific IgE

Fluoroenzymeimmunoassay

Calibrator Range 0-100 kU/l

Directions for Use 52-5291-EN/09

INTENDED USE

ImmunoCAP Specific IgE is an in vitro test system for the quantitative measurement of allergen specific IgE in human serum or plasma. It is intended for in vitro diagnostic use as an aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings, and is to be used in clinical laboratories. ImmunoCAP Specific IgE is to be used with the instruments Phadia 100, Phadia 200, Phadia 250, Phadia 1000, Phadia 2500 or Phadia 5000.

SUMMARY AND EXPLANATION OF THE TEST

In patients suffering from extrinsic asthma, hay fever or atopic eczema, symptoms develop immediately after exposure to specific allergens. This immediate (atopic or anaphylactic) type of allergy is a function of a special type of serum antibodies belonging to the IgE class of immunoglobulins (1, 2).

PRINCIPLE OF THE PROCEDURE

The allergen of interest, covalently coupled to ImmunoCAP, reacts with the specific IgE in the patient sample. After washing away non-specific IgE, enzyme labeled antibodies against IgE are added to form a complex. Following incubation, unbound enzyme-anti-IgE is washed away and the bound complex is then incubated with a developing agent. After stopping the reaction, the fluorescence of the eluate is measured. The higher the response value, the more specific IgE is present in the sample. To evaluate the test results, the responses for the patient samples are transformed to concentrations with the use of a calibration curve.

REAGENTS AND MATERIAL

Reagents are packaged as described below, each purchased separately. The two digit suffix (-xx) on the article number may vary between countries. All kits are not available in all countries. The expiration date and storage temperature are stated on the labels. Do not use reagents beyond their expiration dates.

Note: It is not recommended to pool any reagents.

Keep the ImmunoCAP carrier closed to avoid evaporation of buffer.

Reagents for Phadia 100

- **ImmunoCAP Specific IgE 0-100** (Art No 10-9462-01: for 96 determinations)
 - Specific IgE Conjugate (1 vial)
 - Specific IgE Curve Control 1 (CC-1) (2 single dose vials)
 - Specific IgE Curve Control 2 (CC-2) (2 single dose vials)
- **ImmunoCAP Specific IgE Conjugate 0-100** (Art No 10-9463-01: for 6 x 96 determinations)
- **ImmunoCAP Specific IgE Calibrators 0-100** (Cal-xx) (Art No 10-9460-01: for 1 calibration curve)
- **ImmunoCAP Specific IgE Curve Controls** (CC-1 and CC-2) (Art No 10-9408-01: 3 single dose vials)
- **ImmunoCAP Specific IgE Anti-IgE** (a_IgE) (Art No 14-4417-01: carriers of 16 ImmunoCAP)
- **ImmunoCAP Allergen** (See Product catalogue: carriers of 16 or 10 ImmunoCAP)
- **ImmunoCAP Total IgE Low Range** (low) (Art No 14-4497-35: for 48 determinations)
- **ImmunoCAP Phadiatop** (phad) (Art No 14-4405-35: for 48 determinations)
- **ImmunoCAP Phadiatop Infant** (phinf) (Art No 14-4510-35: for 48 determinations)
- **Development Solution** (Art No 10-9478-01: for 600 determinations)
- **Stop Solution** (Art No 10-9479-01: for 600 determinations)
- **Washing Solution** (Art No 10-9422-01: 6 x 1 l)
 - Washing Solution Additive, 6 x 17.2 ml
 - Washing Solution Concentrate, 6 x 80 ml
- **Washing Solution** (Art No 10-9202-01: 2 x 5 l)
 - Washing Solution Additive, 2 x 86 ml
 - Washing Solution Concentrate, 2 x 400 ml
- **ImmunoCAP Specific IgE Control L** (Art No 10-9528-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Control M** (Art No 10-9529-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Control H** (Art No 10-9530-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Negative Control** (Art No 10-9445-01: for 6 x 4 determinations)

Reagents for Phadia 200

- **ImmunoCAP Specific IgE Conjugate 100** (Art No 10-9316-01: for 6 x 100 determinations)
- **ImmunoCAP Specific IgE Conjugate 400** (Art No 10-9310-01: for 6 x 400 determinations)

- **ImmunoCAP Specific IgE Calibrator Strip 0-100** (Art No 10-9459-01: for 5 calibration curves)
- **ImmunoCAP Specific IgE Curve Control Strip** (CC-1 and CC-2) (Art No 10-9312-01: 5 x 3 sets of curve control)
- **ImmunoCAP Specific IgE Anti-IgE** (a_IgE) (Art No 14-4417-01: carriers of 16 ImmunoCAP)
- **ImmunoCAP Allergen** (See Product catalogue: carriers of 16 or 10 ImmunoCAP)
- **ImmunoCAP Total IgE Low Range** (low) (Art No 14-4497-35: for 48 determinations)
- **ImmunoCAP Phadiatop** (phad) (Art No 14-4405-35: for 48 determinations)
- **ImmunoCAP Phadiatop Infant** (phinf) (Art No 14-4510-35: for 48 determinations)
- **Development Solution** (Art No 10-9441-01: for 6 x 200 determinations; Art No 10-9440-01: for 6 x 315 determinations)
- **Stop Solution** (Art No 10-9442-01: for 6 x 185 determinations; Art No 10-9479-01: for 6 x 100 determinations)
- **Washing Solution** (Art No 10-9422-01: 6 x 1 l)
 - Washing Solution Additive, 6 x 17.2 ml
 - Washing Solution Concentrate, 6 x 80 ml
- **Washing Solution** (Art No 10-9202-01: 2 x 5 l)
 - Washing Solution Additive, 2 x 86 ml
 - Washing Solution Concentrate, 2 x 400 ml
- **ImmunoCAP Specific IgE Control L** (Art No 10-9528-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Control M** (Art No 10-9529-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Control H** (Art No 10-9530-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Negative Control** (Art No 10-9445-01: for 6 x 4 determinations)

Reagents for Phadia 250

- **ImmunoCAP Specific IgE Conjugate 100** (Art No 10-9316-01: for 6 x 100 determinations)
- **ImmunoCAP Specific IgE Conjugate 400** (Art No 10-9310-01: for 6 x 400 determinations)
- **ImmunoCAP Specific IgE Calibrator Strip 0-100** (Art No 10-9459-01: for 5 calibration curves)
- **ImmunoCAP Specific IgE Curve Control Strip** (CC-1 and CC-2) (Art No 10-9312-01: 5 x 3 sets of curve control)
- **ImmunoCAP Specific IgE Anti-IgE** (a_IgE) (Art No 14-4417-01: carriers of 16 ImmunoCAP)
- **ImmunoCAP Allergen** (See Product catalogue: carriers of 16 or 10 ImmunoCAP)
- **ImmunoCAP Total IgE Low Range** (low) (Art No 14-4497-35: for 48 determinations)
- **ImmunoCAP Phadiatop** (phad) (Art No 14-4405-35: for 48 determinations)
- **ImmunoCAP Phadiatop Infant** (phinf) (Art No 14-4510-35: for 48 determinations)
- **Development Solution** (Art No 10-9441-01: for 6 x 200 determinations; Art No 10-9440-01: for 6 x 315 determinations)
- **Stop Solution** (Art No 10-9442-01: for 6 x 185 determinations)
- **Washing Solution** (Art No 10-9422-01: 6 x 1 l)
 - Washing Solution Additive, 6 x 17.2 ml
 - Washing Solution Concentrate, 6 x 80 ml
- **Washing Solution** (Art No 10-9202-01: 2 x 5 l)
 - Washing Solution Additive, 2 x 86 ml
 - Washing Solution Concentrate, 2 x 400 ml
- **ImmunoCAP Specific IgE Control L** (Art No 10-9528-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Control M** (Art No 10-9529-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Control H** (Art No 10-9530-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Negative Control** (Art No 10-9445-01: for 6 x 4 determinations)

Reagents for Phadia 1000

- **ImmunoCAP Specific IgE Conjugate 100** (Art No 10-9316-01: for 6 x 100 determinations)
- **ImmunoCAP Specific IgE Conjugate 400** (Art No 10-9310-01: for 6 x 400 determinations)
- **ImmunoCAP Specific IgE Calibrator Strip 0-100** (Art No 10-9459-01: for 5 calibration curves)
- **ImmunoCAP Specific IgE Curve Control Strip** (CC-1 and CC-2) (Art No 10-9312-01: 5 x 3 sets of curve control)
- **ImmunoCAP Specific IgE Anti-IgE** (a_IgE) (Art No 14-4417-01: carriers of 16 ImmunoCAP)
- **ImmunoCAP Allergen** (See Product catalogue: carriers of 16 or 10 ImmunoCAP)
- **ImmunoCAP Total IgE Low Range** (low) (Art No 14-4497-35: for 48 determinations)
- **ImmunoCAP Phadiatop** (phad) (Art No 14-4405-35: for 48 determinations)
- **ImmunoCAP Phadiatop Infant** (phinf) (Art No 14-4510-35: for 48 determinations)
- **Development Solution** (Art No 10-9439-01: for 6 x 1200 determinations; Art No 10-9314-01: for 6 x 2000 determinations)
- **Stop Solution** (Art No 34-2271-51: for 1200 determinations)

- **Washing Solution** (Art No 10-9202-01: 2 x 5 l)
 - Washing Solution Additive, 2 x 86 ml
 - Washing Solution Concentrate, 2 x 400 ml
- **ImmunoCAP Specific IgE Control L** (Art No 10-9528-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Control M** (Art No 10-9529-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Control H** (Art No 10-9530-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Negative Control** (Art No 10-9445-01: for 6 x 4 determinations)

Reagents for Phadia 2500 and Phadia 5000

- **ImmunoCAP Specific IgE Conjugate 400** (Art No 10-9310-01: for 6 x 400 determinations)
- **ImmunoCAP Specific IgE Calibrator Strip 0-100** (Art No 10-9459-01: for 5 calibration curves)
- **ImmunoCAP Specific IgE Curve Control Strip** (CC-1 and CC-2) (Art No 10-9312-01: 5 x 3 sets of curve control)
- **ImmunoCAP Specific IgE Anti-IgE** (a_IgE) (Art No 14-4417-01: carriers of 16 ImmunoCAP)
- **ImmunoCAP Allergen** (See Product catalogue: carriers of 16 or 10 ImmunoCAP)
- **ImmunoCAP Total IgE Low Range** (low) (Art No 14-4497-35: for 48 determinations)
- **ImmunoCAP Phadiatop** (phad) (Art No 14-4405-35: for 48 determinations)
- **ImmunoCAP Phadiatop Infant** (phinf) (Art No 14-4510-35: for 48 determinations)
- **Development Solution** (Art No 10-9314-01: for 6 x 2000 determinations)
- **Stop Solution** (Art No 34-2337-11: for 4600 determinations)
- **Washing Solution Additive** (Art No 10-9518-01: 4 x 850 ml)
- **Washing Solution Concentrate** (Art No 34-2337-21: 1 x 2800 ml)
- **ImmunoCAP Specific IgE Control L** (Art No 10-9528-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Control M** (Art No 10-9529-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Control H** (Art No 10-9530-01: for 6 x 4 determinations)
- **ImmunoCAP Specific IgE Negative Control** (Art No 10-9445-01: for 6 x 4 determinations)

Details of reagents

ImmunoCAP Specific IgE Conjugate/Conjugate 100/Conjugate 400	
β-Galactosidase-anti-IgE Approximately 1 µg/ml (mouse monoclonal antibodies) Sodium azide 0.06%	Ready for use. Store at 2 – 8 °C until expiration date. Do not freeze!

ImmunoCAP Specific IgE Calibrators/Calibrator Strip 0-100	
(human IgE in buffer) Conc. 0; 0.35; 0.7; 3.5; 17.5 and 100 kU/l Preservative* <0.003%	Ready for use. Store at 2 – 8 °C until expiration date.

ImmunoCAP Specific IgE Curve Controls/Curve Control Strip	
(human IgE in buffer) Preservative* <0.003%	Ready for use. Store at 2 – 8 °C until expiration date.

ImmunoCAP Specific IgE Anti-IgE	
(mouse monoclonal antibodies) Preservative* <0.0015%	Ready for use. Store at 2 – 8 °C until expiration date.

ImmunoCAP Allergen	
Preservative* <0.0015%	Ready for use. Store at 2 – 8 °C until expiration date.

ImmunoCAP Total IgE Low Range	
ImmunoCAP Anti-IgE (mouse monoclonal antibodies) Preservative* <0.0015%	Ready for use. Store at 2 – 8 °C until expiration date.

ImmunoCAP Phadiatop	
Preservative* <0.0015%	Ready for use. Store at 2 – 8 °C until expiration date.

ImmunoCAP Phadiatop Infant	
Preservative* <0.0015%	Ready for use. Store at 2 – 8 °C until expiration date.

Development Solution	
4-Methylumbelliferyl- β -D-galactoside 0.01% Preservative* <0.0010%	Ready for use. Store at 2 – 8 °C until expiration date. Do not freeze!

Stop Solution	
Sodium carbonate 4%	Ready for use. Store at 2 – 32 °C until expiration date.

Washing Solution	
For information, see separate Directions for Use for Washing Solution.	

ImmunoCAP Specific IgE Control L	
Sodium azide 0.05%	Ready for use. Store at 2 – 8 °C until expiration date.
ImmunoCAP Specific IgE Control L is prepared from selected pooled human samples and contains IgE antibodies to the allergen e1.	

ImmunoCAP Specific IgE Control M	
Sodium azide 0.05%	Ready for use. Store at 2 – 8 °C until expiration date.
ImmunoCAP Specific IgE Control M is prepared from selected pooled human samples and contains IgE antibodies to the allergen t3.	

ImmunoCAP Specific IgE Control H	
Sodium azide 0.05%	Ready for use. Store at 2 – 8 °C until expiration date.
ImmunoCAP Specific IgE Control H is prepared from selected pooled human samples and contains IgE antibodies to the allergen d1.	

ImmunoCAP Specific IgE Negative Control	
Sodium azide 0.05%	Ready for use. Store at 2 – 8 °C until expiration date.
ImmunoCAP Specific IgE Negative Control is prepared from selected pooled human samples.	

ImmunoCAP IgE/ECP/Tryptase Sample Diluent	
(buffer solution with Bovine Serum Albumin) Preservative* <0.003%	Ready for use. Store at 2 – 8 °C until expiration date.

***Preservative:** Mixture of 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1).

Additional material

Additional products available from Phadia AB:

- ImmunoCAP IgE/ECP/Tryptase Sample Diluent (10-9256-01/10-9360-01/10-9541-01)

Materials required but not provided by Phadia AB:

- Measuring cylinder 1000 ml
- Purified water (14, 15) or Clinical Laboratory Reagent Water (CLRW, 16)



Precautions

- For in vitro diagnostic use. Not for internal or external use in humans or animals.

- Some reagents are manufactured from human blood components. The source materials have been tested by immunoassay for hepatitis B surface antigen, for antibodies to HIV1, HIV2 and hepatitis C virus and found to be negative. Nevertheless, all recommended precautions for the handling of blood derivatives should be observed. Please refer to Human Health Service (HHS) Publication No. (CDC) 93-8395 or other local/national guidelines on laboratory safety procedures.
- Reagents containing >0.0015% mixture of 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) may cause sensitization by skin contact. Avoid contact with skin. Wear suitable gloves. For more information see Safety Data Sheet.

INSTRUMENTS

Phadia 100 and Phadia 200 process all steps of the assay and print results automatically after the assay is completed^(a). Phadia 250, Phadia 1000, Phadia 2500 and Phadia 5000 are continuous random access systems that perform all steps of the assay^(a).

On board stability

Phadia 100 has no provisions for on board reagent storage. Information on reagent storage for the intended locations on the other Phadia instruments is shown below.

	Phadia 200	Phadia 250	Phadia 1000	Phadia 2500, Phadia 5000
Calibrator/ Curve Control	28 days.			N/A
Conjugate	4 days. Recap bottles every night.		7 days.	
Development Solution	5 days. Recap bottles every night.		14 days.	5 days.
Stop Solution	14 days. Recap bottles every night.		14 days.	31 days.
Washing Solution (prepared solution)	7 days. Discard every seventh day and perform weekly maintenance according to respective instrument user manual.			
Washing Solution Concentrate	N/A			30 days.
Washing Solution Additive	N/A			30 days.
Sample Diluent	7 days. Recap bottles every night.		N/A	
ImmunoCAP Carrier	No provision for on board storage.	Until expiration date.		

SPECIMEN COLLECTION AND PREPARATION

Specimen collection

Serum and plasma (EDTA or heparin) samples from venous or capillary blood can be used. Collect blood samples using standard procedures. Keep specimens at room temperature (RT) for shipping purposes only. Store at 2 °C to 8 °C up to one week, or else at –20 °C. Avoid repeated freezing and thawing (3). For further reading on interfering substances, see reference (4).

Note: It is the responsibility of the individual laboratory to use all available references and/or its own studies to determine specific stability criteria for its laboratory. In general, laboratories should perform validation studies before implementing a change in specimen acceptance criteria (18).

Note: Blood samples for testing with drugs and venom ImmunoCAP should be collected during or close to the event, preferably not later than 6 months after exposure. If the test result is negative and an IgE-mediated reaction is still strongly suspected, it is advisable to draw a new sample and repeat the test at 5 to 6 weeks. (5, 6)

Preparation of samples

Sample dilution is usually not required.

For determination of values higher than 100 kU_A/l IgE, dilute the samples with ImmunoCAP IgE/ECP/Tryptase Sample Diluent.

Handling of control specimen

It is recommended to remove and recap the control vials from the instrument as soon as the pipetting of the samples is finished and the sample incubation is started. It is also recommended to gently stir the vial before use.

ImmunoCAP Specific IgE Controls should be treated in the same way as a patient sample in the procedure. ImmunoCAP Specific IgE Controls are ready for use and must not be further diluted.

PROCEDURES

Procedural steps^(a)

For procedural steps, see **Notes a**.

Parameters of the procedure

Patient samples are run in single determinations.

Volumes per determination:

Sample	40 μ l
Conjugate	50 μ l
Development Solution	50 μ l
Stop Solution	600 μ l

Incubations are performed at 37 °C by Phadia instruments.

Phadia 100: Total time for one assay is 2.5 hours.

Phadia 200: Total time for one assay is up to 4 hours.

Phadia 250, Phadia 1000, Phadia 2500 and Phadia 5000: The process time is 1 hour and 45 minutes from entering the first sample until the result is available.

Calibration^(a)

ImmunoCAP Specific IgE Calibrators or ImmunoCAP Specific IgE Calibrator Strips are run in duplicates to obtain a calibration curve. The curve can be stored. The software for Phadia instruments has built-in acceptance limits for the calibration curve and the curve controls. Use two curve controls, CC-1 and CC-2, each in single determination to evaluate subsequent assays against the stored curve.

Calibrator range: 0-100 kU/l.

Reference material: The IgE calibrators are traceable (via an unbroken chain of calibrations) to the 2nd International Reference Preparation (IRP) 75/502, or the equivalent 3rd International Standard 11/234, of Human Serum Immunoglobulin E from World Health Organization (WHO) (17).

QUALITY CONTROL

Record keeping for each assay

It is good laboratory practice to record the lot numbers of the components used, the dates when they were first opened and the remaining volumes.

Control specimen

Good laboratory practice requires that quality control specimen should be included in every run. Any material used should be assayed repeatedly to establish mean values and acceptable ranges.

Controls available from Phadia AB for day to day quality control:

- ImmunoCAP Specific IgE Control L (10-9528-01)
- ImmunoCAP Specific IgE Control M (10-9529-01)
- ImmunoCAP Specific IgE Control H (10-9530-01)
- ImmunoCAP Specific IgE Negative Control (10-9445-01)

Intended use

ImmunoCAP Specific IgE Controls are used for monitoring ImmunoCAP Specific IgE measurements performance in Phadia instruments.

Expected values for positive ImmunoCAP Specific IgE Controls

As with all immunoassays the results are affected by the testing procedures and equipment used by different laboratories. It is therefore recommended that each laboratory establishes its own target value for each actual lot of control together with criteria of acceptance (recommended range \pm 30%).

This established target value is expected to fall within the range for the actual lot. The range is stated on the vial for:

- ImmunoCAP Specific IgE Control L
- ImmunoCAP Specific IgE Control M
- ImmunoCAP Specific IgE Control H

The range for each specific lot is calculated as a mean \pm 2 SD using the expected long term variation. The mean value for each specific lot has been determined from at least 8 consecutive control assays, each in a minimum of 6 replicates using ImmunoCAP Specific IgE.

Expected values for ImmunoCAP Specific IgE Negative Control

The negative control will give results representative for non-atopic blood donors using any of the following ImmunoCAP Allergens:

- ImmunoCAP Allergen e1, Cat dander (14-4109-01)
- ImmunoCAP Allergen t3, Common silver birch (14-4102-01)
- ImmunoCAP Allergen d1, House dust mite (14-4107-01)

Expected values are below 0.1 kU_A/l.

Proficiency testing

An external quality assessment program (proficiency testing) is available from Phadia AB for quality assurance purposes (Quality Club):

- Quality Club Specific IgE (10-9298-01)

RESULTS

For Phadia instruments using Phadia Information Data Manager Software or Phadia Prime, all calculations are automatically performed^(a). Phadia 100 is programmed to automatically calculate all results^(a). It can also be used with Phadia Information Data Manager Software.

ImmunoCAP Specific IgE antibody concentration (kU_A/l)

ImmunoCAP Specific IgE Calibrators are used for determination of specific IgE antibodies and values are expressed in kU_A/l, where A represents allergen-specific antibodies. Values above the limit of quantitation represent a progressive increase in the concentration of allergen-specific antibodies (7).

Calculations of results for other applications of specific IgE are provided in the DFUs for:

- ImmunoCAP Phadiatop (Art No 14-4405-35)
- ImmunoCAP Phadiatop Infant (Art No 14-4510-35)
- ImmunoCAP Total IgE Low Range (Art No 14-4497-35)

Interpretation of results for ImmunoCAP Allergen mixes

Results for ImmunoCAP Allergen mixes are qualitative values and 0.35 kU/l is recommended as a cut-off value.

Values ≥0.35 kU/l indicate specific IgE antibodies to one or more of the allergens coupled to ImmunoCAP Allergen mixes.

A value below 0.35 kU/l indicates undetectable levels or very low levels, of allergen specific IgE antibodies. Deviations from results obtained with single ImmunoCAP Allergen(s) may occur.

Reinvestigation with appropriate single ImmunoCAP Allergen(s) is recommended when there is a need to further identify and obtain a quantitative result for the specific allergen(s).

The interpretation of results obtained with ImmunoCAP Allergen mixes cannot be compared with the results with single ImmunoCAP Allergen. The degree of positivity of ImmunoCAP Allergen mixes cannot be considered the cumulative degree of positivity of the respective single ImmunoCAP Allergen.

LIMITATIONS OF THE PROCEDURE

A definitive clinical diagnosis should only be made by the physician after all clinical and laboratory findings have been evaluated. It should not be based on the results of any single diagnostic method.

- Very low levels of allergen specific IgE antibodies should be evaluated with caution when:
 - a. total IgE values are above 1000 kU/l
 - b. total IgE values are above 500 kU/l when testing for specific IgE antibodies to beta-lactams and chlorhexidine (ImmunoCAP Allergen c1, c2, c5, c6, c7 & c8)
- In food allergy, circulating IgE antibodies may remain undetectable despite a convincing clinical history. The antibodies may be directed towards allergens that are revealed or altered during industrial processing, cooking or digestion and therefore do not exist in the original food for which the patient is tested.
- Results below limit of quantitation obtained for a drug- or venom specific IgE determination indicates the absence of specific IgE antibodies to that drug or venom. Such results do not preclude existence of current or future clinical hypersensitivity to drugs or venoms (5, 6, 8, 9).
- Samples with results below limit of quantitation obtained with ImmunoCAP Allergen Components are recommended to be tested with the corresponding extract based ImmunoCAP Allergen, if not already performed. Additional extract based testing will cover additional allergen components present in the allergen source material to which the patient may be sensitized.
- A result below limit of quantitation obtained with an extract based ImmunoCAP Allergen never excludes the possibility of obtaining measurable concentrations of specific IgE when testing with ImmunoCAP Allergen Components from the same allergen source. This is due to the fact that some components may be present in very low amounts in the natural extract.

EXPECTED VALUES^(b)

Good laboratory practice recommends that each laboratory establishes its own expected range of values.

When a pool from 31 healthy non-allergic blood donors was tested against the existing panel of ImmunoCAP Specific IgE allergens, the 95 percentile was below 0.1 kU_A/l.

In clinical practice, 0.35 kU_A/l has commonly been used as a cut off and a large number of studies have been performed in which the clinical performance of ImmunoCAP Specific IgE tests in allergy diagnosis has been evaluated. Clinical performance expressed as sensitivity, ranging from 84-95%, and specificity, ranging from 85-94%, has been reported from multi-center studies including several hundred patients tested for a range of different allergens (10, 11, 12).

Expected values for other applications of specific IgE are provided in the DFUs for:

- ImmunoCAP Phadiatop (Art No 14-4405-35)
- ImmunoCAP Phadiatop Infant (Art No 14-4510-35)
- ImmunoCAP Total IgE Low Range (Art No 14-4497-35)

PERFORMANCE CHARACTERISTICS**Instrument comparison**

Comparison studies^(b) have been performed with different combinations of Phadia instruments, including more than 180 patient samples and more than 45 ImmunoCAP Allergens. The results obtained show good concordance between instruments.

Precision^(b)

The following pooled coefficients of variation have been obtained with Phadia 1000 when testing representative allergens from 7 allergen groups. Each sample has been assayed in 2 replicates on 18 different occasions using stored calibration curves. The values are representative for all Phadia instruments.

Sample level (kU _A /l)	Coefficients of variation (%)	
	Within assay	Between assay
0.35 – 1.5	4	4
1.5 – 50	5	5
50 – 100	5	9

Analytical sensitivity^(b)

The overall limit of quantitation (13) for allergen specific IgE antibodies is 0.1 kU_A/l.












Analytical specificity^(b)

The cross-reactivity with other human immunoglobulins is non-detectable at physiological concentrations of IgA, IgD, IgM and IgG.

WARRANTY

The performance data presented here was obtained using the procedure indicated. Any change or modification in the procedure not recommended by Phadia AB may affect the results, in which event Phadia AB disclaims all warranties expressed, implied or statutory, including the implied warranty of merchantability and fitness for use. Phadia AB and its authorized distributors, in such event, shall not be liable for damages indirect or consequential.

SYMBOLS

	Use-by date		Contains sufficient for <n> tests
	Batch code		<i>In vitro</i> diagnostic medical device
	Date of manufacture		Temperature limit
	Catalogue number		Consult instructions for use
	Caution		Biological risks
	Manufacturer		

Full symbol glossary is available at: https://symbols_glossary.phadia.com.

REFERENCES

1. Wide L, Bennich H, Johansson SGO. Diagnosis of allergy by an in vitro test for allergen antibodies. *Lancet* 1967;2:1105-7.

2. Johansson SGO, Yman L. In vitro assays for immunoglobulin E. *Clin Rev Allergy* 1988;6(2):93-139.
3. CSLI. Analytical Performance Characteristics and Clinical Utility of Immunological Assays for Human Immunoglobulin E (IgE) Antibodies and Defined Allergen Specificities; Approved Guideline – Second Edition. I/LA20-A2 Vol. 29 No. 9.
4. Tate J, Ward G. Interference in Immunoassay. *Clin Biochem Rev* 2004;25:105-120.
5. Guttormsen A.B, Johansson S.G.O, Öman H., Wilhelmson V., Nopp A. No consumption of IgE antibody in serum during allergic drug anaphylaxis. *Allergy* 2007; 62: 1326-1330.
6. Goldberg A., Confino-Cohen R. Timing of venom skin tests and IgE determinations after insect sting anaphylaxis. *J Allergy Clin Immunol* 1997; 100:182-184.
7. Yman L. The new generation of allergy testing. Data on file.
8. Wide L, Juhlin L. Detection of penicillin allergy of the immediate type by radio-immunoassay of reagins (IgE) to penicilloyl conjugates. *Clin Allergy* 1971; 1: 171-7.
9. Kraft D, Wide L. Clinical patterns and results of radioallergosorbent test (RAST) and skin tests in penicillin allergy. *Br J Dermatol* 1976;94:593-601.
10. Johansson SGO, ed. Clinical Workshop. IgE antibodies and the Pharmacia CAP System in allergy diagnosis. Lidköping: Landströms 1988.
11. Pastorello EA, Incorvaia C, Pravettoni V, Bonini S, Canonica GV, Ortoloni C et al. A multicentric study on sensitivity and specificity of a new in vitro test for measurement of IgE antibodies. *Ann Allergy* 1991;67:365-70.
12. Paganelli R, Ansoategui IJ, Sastre J, Lange CE, Roovers MH, de Groot H, et al. Specific IgE antibodies in the diagnosis of atopic disease. Clinical evaluation of a new in vitro test system, UniCAP, in six European allergy clinics. *Allergy* 1998;53(8):763-8.
13. NCCLS EP17-A. Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline – First Edition, National Committee for Clinical Laboratory Standards, 2004.
14. US Pharmacopeia & National Formulary, current edition.
15. European Pharmacopoeia, current edition.
16. CLSI C3-A4, Preparation and Testing of Reagent Water in the Clinical Laboratory, Approved Guideline-Fourth Edition, Clinical and Laboratory Standards Institute, 2006.
17. Thorpe S, Heath A, Fox B, Patel D, Egner W. The 3rd International Standard for serum IgE: international collaborative study to evaluate a candidate preparation. *Clin Chem Lab Med* 2014; 52(9): 1283-1289.
18. CLSI. Procedures for the Handling and Processing of Blood Specimens for Common Laboratory Tests; Approved Guideline-Forth Edition. CLSI document H18-A4, Wayne, PA: Clinical and Laboratory Standards Institute; 2010.

Notes

^(a)For more information, see Phadia 100, Phadia 200, Phadia 250, Phadia 1000 and/or Phadia 2500/Phadia 5000 User Manual.

^(b)Studies performed at Phadia AB, Uppsala, Sweden.

Patents/Trademarks

The following designations are trademarks belonging to Phadia AB: ImmunoCAP, Phadia, Phadiatop, Quality Club.

Trademark change: Phadia AB has changed the trademarks of the instrument platforms from "UniCAP™" and "ImmunoCAP™" to "Phadia™". The new name has been applied to the instruments and related items, e.g. Software and User Manuals. The trademark "ImmunoCAP™" has been removed from the System Reagents. This is a trademark change only; the change has no impact on performance or safety.

Addresses

AUSTRIA Thermo Fisher Diagnostics Austria GmbH
Dresdner Str. 89
A-1200 Vienna
Tel: +43-1 270 2020 Fax: +43-1 270 202020

BELGIUM Thermo Fisher Diagnostics NV
Pontbeekstraat 2
BE-1702 GROOT-BIJGAARDEN
Tel: +32-2 749 55 15 Fax: +32-2 749 55 23

BRAZIL Phadia Diagnósticos Ltda.
Rua Eugênio de Medeiros, 303 cj 1101C
05425-000 São Paulo – SP
Tel: +55 0800 5515 355

CHINA Thermo Fisher Scientific (China) Co., Ltd.
Building 6-7
No. 27 Xin Jin Qiao Road
Shanghai 201102
P.R. China

Tel. +86 800 810 5118 Fax. +86 21 6100 21288

CZECH REPUBLIC

Thermo Fisher Scientific, Phadia s.r.o.
Drahobejlova 1019/27

19000 PRAHA 9
Tel: +420 220 518 743 Fax: +420 220 518 743

DENMARK Thermo Fisher Diagnostics ApS
Gydevang 33
DK-3450 ALLERØD

Tel: +45-70 23 33 06 Fax: +45-70 23 33 07

FINLAND Phadia Oy

Ratastie 2
P.O. Box 100
FI-01621

Tel: +358 10 3292 110 Fax: +358 10 3292 531

FRANCE Thermo Fisher Diagnostics S.A.S.
CS60610

FR-78056 ST QUENTIN-YVELINES CEDEX
Tel: +33-1 61 37 34 30 Fax: +33-1 30 64 62 37

GERMANY Thermo Fisher Diagnostics GmbH
Munzinger Str. 7, D-79111 FREIBURG

Tel: +49-761 47 805-0 Fax: +49-761 47805-338

Mail: Thermo Fisher Diagnostics GmbH

Postfach 1050 DE-790 10 FREIBURG

HONG KONG

Thermo Fisher Scientific (Hong Kong) Limited

Units 01, 09-13 & 15-18, Level 13, Tower 1

Kowloon Commerce Centre

No. 51 Kwai Cheong Road, Kwai Chung

New Territories, Hong Kong

Tel: +852 3107 7600 Fax: +852 2567 4447

INDIA Thermo Fisher Scientific India Pvt. Ltd

Unit No.07, 10 & 11, ground floor,

Splendor forum, plot no 03

Jasola, District Centre,

NEW DEHLI-110025

Tel: +91 11 49375400

IRELAND Thermo Fisher Diagnostics (Ireland) Ltd.

16 Shenley Pavilions, Chalkdell Drive

Shenley Wood, Milton Keynes, MK5 6LB

Tel: +44 1908 76 91 10 Fax: +44 844 324 94

ITALY Thermo Fisher Diagnostics S.p.A.

Via G. B. Tiepolo, 18

IT-20900 MONZA (MB)

Tel: +39 039 8389.1 Fax: +39 039 838 9329

JAPAN Thermo Fisher Diagnostics K.K.

Sumitomo Fudosan Mita Twin Bldg. East 4F

4-2-8 Shibaura, Minato-ku,

Tokyo 108-0023, Japan

Tel: +81 3 6872 6200 Fax: +81 3 6872 6220

KOREA Thermo Fisher Scientific Korea Ltd.

11-12FL, Suseo Office Building

281,Gwangpyeong-ro, Gangnam-gu,

Seoul 06349, Korea

Tel: +82 2 6196 5556-9 Fax: +82 2 6196 5555

THE NETHERLANDS Thermo Fisher Diagnostics B.V.

Postbus 696

NL-3430 AR NIEUWEGEIN

Tel: +31-30 602 37 00 Fax: +31-30 602 37 09

NORWAY Thermo Fisher Diagnostics AS

Postboks 114, Smestad

NO-0309 OSLO

Tel: +47-21 67 32 80

PORTUGAL Thermo Fisher Diagnostics,

Sociedade Unipessoal Lda

Lagoas Park - Edifício n°11 - Piso 0

PT-2740-270 PORTO SALVO

Tel: +351-214 23 53 50 Fax: +351-214 21 60 36

SOUTH AFRICA Laboratory Specialities (Pty)

t/a Thermo Fisher Scientific

Thermo Fisher Scientific Building

Unit A, 3 Susan Street

Strijdom Park, Randburg 2169

Tel: +27 11 792 6790 Fax: +27 11 793 1064

SPAIN Thermo Fisher Diagnostics S.L.U.

Avda. Alcalde Barnils n° 70 Planta 2

Edificio Onada

08174 Sant Cugat del Vallés, Barcelona

Tel: +34-935 765 800 Fax: +34-935 765 820

SWEDEN Thermo Fisher Diagnostics AB

C/o Phadia AB

P O Box 6460 SE-751 37 UPPSALA

Tel: +46-18 16 60 60 Fax: +46-18 16 63 24

SWITZERLAND Thermo Fisher Diagnostics AG

Sennweidstrasse 46

CH-6312 STEINHAUSEN

Tel: +41-43 343 40 50 Fax: +41-43 343 40 51

TAIWAN Phadia Taiwan Inc.

6F-1, No. 85, Jhouzih St., NeiHu District

Taipei, Taiwan, Republic of China

Tel. +886 2 8751 6655 Fax. +886 2 8751 5353

UNITED KINGDOM Thermo Fisher Diagnostics Ltd

16 Shenley Pavilions, Chalkdell Drive

Shenley Wood, Milton Keynes, MK5 6LB

Tel: +44-1908 76 91 10 Fax: +44-844 324 94 95

USA Phadia US Inc.

4169 Commercial Avenue

Portage, Michigan 49002

Tel: +1 800-346-4364 (Toll Free) Fax: +1 269 492-7541

OTHER COUNTRIES Phadia AB,

Distributor Sales

P O Box 6460, SE-751 37 UPPSALA

Tel: +46 18 16 50 00 Fax: +46 18 16 63 65



Phadia AB,

Rapskatan 7P, P. O. Box 6460, 751 37 Uppsala, Sweden

Tel: +46 18 16 50 00 Fax: +46 18 14 03 58



Issued October 2011. Revised September 2018.

© Phadia AB, Uppsala, Sweden.